Janice Tsang, MD
Specialist in Medical Oncology
Hon. Clinical Assistant Professor
Li Ka Sing Faculty of Medicine
The University of Hong Kong
Why have molecular drivers for cancer therapy been embraced by the academic oncology community in China, and what role does NGS testing and comprehensive genomic profiling—such as that provided by FoundationOne and other laboratories—currently ...
Can you contrast and compare different platforms for genomic profiling—hot spot panels, mammoprint, CGP with hybrid capture, and others—and explain why CGP platforms, such FoundationOne, with hybrid capture have emerged as the gold standard?
What specific molecular targets are detected by the NGS hybrid capture platform, how is actionability determined, and what are the translational implications of molecular drivers across the cancer spectrum?
At what point in the natural history of a cancer, in the individual patient, do you recommend that NGS-CGP with a hybrid capture-based platform like FoundationOne be performed? And what do you do with this information at each point in time?
What is the role of NGS-based mutational testing in patients with triple-negative breast cancer?
What is the role of NGS-based mutational testing in patients with triple-negative breast cancer?
What is the clinical rationale for incorporating genomic target-driven therapies into the front lines of oncology practice? Can we expect NGS to uncover more molecular drivers and actionable mutations over time?
Does FoundationOne’s comprehensive genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Please discuss. Do you know of any other genomic profiling services that are clinically ...